# Development of a Mouse Experimental System for the In Vivo Characterization of Bioengineered Adipose-Derived Stromal Cells

## TL;DR

Researchers developed a mouse model to study how bioengineered fat-derived cells behave and interact with the body after transplantation.

## Contribution

A novel mouse system for in vivo analysis of bioengineered adipose-derived stromal cells and their interactions with recipient cells.

## Key findings

- Immortalized ADSCs retained key characteristics and survived for 1 month post-transplantation.
- Donor ADSCs promoted earlier migration of recipient blood vascular endothelial cells into the transplanted sheets.
- No immune cell accumulation was observed in the transplanted sheets, regardless of donor cell presence.

## Abstract

Human adipose-derived stromal cells (ADSCs) are an important resource for cell-based therapies. However, the dynamics of ADSCs after transplantation and their mechanisms of action in recipients remain unclear. Herein, we generated genetically engineered mouse ADSCs to clarify their biodistribution and post-transplantation status and to analyze their role in recipient mesenchymal tissue modeling. Immortalized ADSCs (iADSCs) retained ADSC characteristics such as stromal marker gene expression and differentiation potential. iADSCs expressing a fluorescent reporter gene were seeded into biocompatible nonwoven fabric sheets and transplanted into the dorsal subcutaneous region of neonatal mice. Transplanted donor ADSCs were distributed as CD90-positive stromal cells on the sheets and survived 1 month after transplantation. Although accumulation of T lymphocytes or macrophages inside the sheet was not observed with or without donor cells, earlier migration and accumulation of recipient blood vascular endothelial cells (ECs) inside the sheet was observed in the presence of donor cells. Thus, our mouse model can help in studying the interplay between donor ADSCs and recipient cells over a 1-month period. This system may be of value for assessing and screening bioengineered ADSCs in vivo for optimal cell-based therapies.